BlackRock’s Oncolytics Biotech ONCY Stock Holding History

BlackRock’s Portfolio ONCY Stock Details ONCY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.55K	Hold	3,000	–	–	﹤0.01%	5504
2025 Q4	$2.62K	Hold	3,000	–	–	﹤0.01%	5381
2025 Q3	$4.2K	Hold	3,000	–	–	﹤0.01%	5278
2025 Q2	$2.32K	Hold	3,000	–	–	﹤0.01%	5313
2025 Q1	$1.65K	Hold	3,000	–	–	﹤0.01%	5307
2024 Q4	$2.74K	Buy	+3,000	New	+$3.12K	﹤0.01%	5268
2020 Q3	–	Sell	-3,895	Closed	-$7K	–	5133
2020 Q2	$7K	Hold	3,895	–	–	﹤0.01%	4812
2020 Q1	$5K	Buy	+3,895	New	+$9.72K	﹤0.01%	4774

Other funds holding ONCY

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

SFP

Sandbox Financial Partners Bethesda, Maryland $356M AUM 19.83% 1-Year Est. Return

Seeds Investor New York $735M AUM 17.54% 1-Year Est. Return

TAM

Tocqueville Asset Management New York $6.74B AUM 32.29% 1-Year Est. Return

EFG

Everhart Financial Group Dublin, Ohio $1.56B AUM 34.29% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Doliver Advisors Houston, Texas $442M AUM 34.09% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

BlackRock's ONCY Position: Q1 2026 in Review

BlackRock held its Oncolytics Biotech (ONCY) position steady in Q1 2026 at 3,000 shares worth $2.55K. The position accounts for ﹤0.01% of the portfolio, ranked #5504.

BlackRock first reported a position in ONCY in Q1 2020 and has held it in 8 quarters since. The position peaked at $7K in Q2 2020. 59 funds tracked by Wall St. Rank hold ONCY as of Q1 2026.

BlackRock held 3,000 shares of Oncolytics Biotech worth $2.55K as of Q1 2026.
BlackRock left its Oncolytics Biotech share count unchanged in Q1 2026.
Oncolytics Biotech made up ﹤0.01% of BlackRock's portfolio in Q1 2026, its #5504 holding.
BlackRock first reported a position in Oncolytics Biotech in Q1 2020 and has held it in 8 quarters since.
BlackRock's Oncolytics Biotech position peaked at $7K in Q2 2020.
59 funds tracked by Wall St. Rank held Oncolytics Biotech as of Q1 2026.

Based on BlackRock's 13F filing for Q1 2026, filed 13 May 2026.